Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q1 2024 · 10-Q
Revenue$1.06M$1.06M+55.9% vs Q1 2023 Net Income-$1.45M-$1.45MN/M vs Q1 2023 EPS Diluted-$0.09-$0.09N/M vs Q1 2023 Gross Profit$666,165+195.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Operating Cash Flow-$357,090N/M Free Cash Flowderived-$362,090N/M Margins · derivedGross margin63.1%+29.8 pt vs Q1 2023
Operating margin-100.1%+90.3 pt vs Q1 2023
Net margin-136.9%+127.5 pt vs Q1 2023
ended Mar 31, 2024 · filed May 6, 2024 · 36 d after period end